Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

102.86 +0.48 (+0.46%)
Streaming Delayed Price Updated: 12:47 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
54 55 Next >
News headline image
FDA Advisors Set To Discuss Abbott's TriClip For Heart Valve Disorder As Questions On Pivotal Trial Loom ↗
FDA to review Abbott's TriClip G4 System for severe tricuspid regurgitation. Circulatory System Devices Panel meeting and insights from the briefing document. 
Via Benzinga
News headline image
Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How. ↗
Abbott Labs has an impressive portfolio of nutrition drinks, and its latest addition could help it profit from a new market: people taking prescribed weight loss drugs. 
Via The Motley Fool
News headline image
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains ↗
Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector. 
Via InvestorPlace
News headline image
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys? ↗
There's room for multiple winners in the fast-growing weight-loss market. 
Via The Motley Fool
News headline image
This Is What Whales Are Betting On Abbott Laboratories ↗
 
Via Benzinga
News headline image
Abbott Laboratories Stock Getting Closer To Key Technical Benchmark ↗
Abbott Laboratories shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
News headline image
Is Abbott Laboratories Stock a Buy Now? ↗
Can Abbott Laboratories be a reliable income stock to hang on to now? 
Via The Motley Fool
News headline image
Looking At Abbott Laboratories's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Looking Into Abbott Laboratories's Recent Short Interest ↗
 
Via Benzinga
News headline image
7 Tremendous Dividend Stocks With Double-Digit 5-Year Growth Rates ↗
When it comes to buying dividend stocks, investors should seek out companies that consistently and repliably grow their payout over time. 
Via InvestorPlace
News headline image
Want to Get Richer? Here Are the 3 Best Stocks to Buy Now and Hold Forever ↗
Healthcare is an excellent place to find some tried and true wealth compounders. 
Via The Motley Fool
News headline image
Healthcare And Life Science Funds And ETFs Performance 2023-2024 ↗
Healthcare stocks usually provide a defensive posture to a stock portfolio. 
Via Talk Markets
Topics ETFs
News headline image
2 Stocks to Buy Near Their 52-Week Highs ↗
It's not too late to invest in these stocks. 
Via The Motley Fool
News headline image
2 Healthcare Dividend Kings to Buy and Hold Forever ↗
It's going to take a lot to interrupt these companies' streaks. 
Via The Motley Fool
News headline image
Cracking The Code: Understanding Analyst Reviews For Abbott Laboratories ↗
 
Via Benzinga
News headline image
Abbott Faces Lawsuit As Grandmother Questions PediaSure's Height Growth Claims ↗
Abbott Laboratories faces a lawsuit questioning the efficacy of PediaSure Grow & Gain nutrition drinks in promoting height growth. 
Via Benzinga
Topics Lawsuit
News headline image
Could Abbott Labs Be the Next Big Winner in the Billion-Dollar Weight Loss Market? ↗
Abbott Labs is using its well-established strengths to make gains in the weight loss market. 
Via The Motley Fool
News headline image
4 med tech stocks with improving prognosis for 2024
MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025. 
Via MarketBeat
News headline image
7 ‘AgeTech’ Stocks to Profit From the Booming Longevity Market ↗
Aging is an inevitability, as much as we try to deny it. Under this context, these AgeTech stocks may prove quite relevant. 
Via InvestorPlace
News headline image
Stock Market Continues To Rally; ASML, Netflix, Tesla, Intel Are Big Earnings Movers: Weekly Review ↗
The S&P 500 and Dow Jones hit fresh record highs on Friday. 
Via Investor's Business Daily
Topics Stocks
News headline image
World's Smallest Brain Stimulation Device For Movement Disorder: FDA Approved Abbott's Liberta RC DBS system ↗
Abbott's Liberta RC DBS system, the world's smallest FDA-approved rechargeable deep brain stimulation device. With only 10 recharges a year, it's compatible with NeuroSphere Virtual Clinic, reducing... 
Via Benzinga
News headline image
Abbott Laboratories on track for new highs in 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact. 
Via MarketBeat
News headline image
Stock Market Extends Record Highs, S&P 500 Hits 4,900 On Tech Rally, Microsoft's $3 Trillion Mark: What's Driving Markets Wednesday? ↗
It’s a bullish day on Wall Street, with major U.S. large-cap indices reaching record highs, driven by broad-based rallies in tech-related stocks as investors continue to embrace the AI trade. 
Via Benzinga
Topics Artificial Intelligence Stocks
News headline image
Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript ↗
ABT earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Abbott Laboratories Surpasses Q4 Sales Expectations, Despite Dip In COVID-19 Testing Demand ↗
Abbott Laboratories exceeds expectations with Q4 sales of $10.24B, showcasing resilience despite softer demand for COVID-19 testing. CEO anticipates continued growth in 2024. 
Via Benzinga
News headline image
Abbott Labs Skids On Light Earnings Guidance Despite Quarterly Sales Beat ↗
Abbott beat sales expectations and earnings came in light for the fourth quarter. 
Via Investor's Business Daily
News headline image
Abbott Laboratories Barely Hits Q4 Target With $1.19 EPS ↗
Abbott Laboratories announces Q4 results with $10.24 billion in revenue and an EPS of $1.19. 
Via Talk Markets
News headline image
Nasdaq, S&P 500 Futures Jump As Wall Street Eagerly Awaits Tesla's Q4 Earnings: Analyst Says Rally Broadening But Favors These Stocks ↗
Earnings have served to mitigate early January's weakness, and sentiment appears to be upbeat going into Wednesday's session. 
Via Benzinga
Topics Stocks
News headline image
Earnings Scheduled For January 24, 2024 ↗
Companies Reporting Before The Bell • Freeport-McMoRan (NYSE:FCX) is estimated to report quarterly earnings at $0.22 per share on revenue of $5.86 billion. 
Via Benzinga
News headline image
Investor Optimism Improves Following Earnings Reports; S&P 500 Reaches Another High ↗
The CNN Money Fear and Greed index showed a further increase in overall market sentiment, while the index remained in the "Greed" zone on Tuesday. U.S. stocks closed mixed on Tuesday, with the Dow... 
Via Benzinga
Topics Stocks
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.